Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jun;68(6):e28961.
doi: 10.1002/pbc.28961. Epub 2021 Mar 4.

Re-thinking transplant for neuroblastoma

Brian H Kushner  1
Affiliations
Comment

Re-thinking transplant for neuroblastoma

Brian H Kushner. Pediatr Blood Cancer. 2021 Jun.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Yamazaki F, Yamasaki K, Kiyotani C, et al. Thiotepa-melphalan myeloablative therapy for high-risk neuroblastoma. Pediatr Blood Cancer. 2021;e28896. https://doi.org/10.1002/pbc.28896
    1. Ladenstein R, Pötschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomized, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500-514.
    1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999;341:1165-1173.
    1. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649-658.
    1. Pritchard J, Cotterill SJ, Germond SM, Imeson J, De Kraker J, Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348-357.

LinkOut - more resources